Evan Y. Snyder earned his M.D. and Ph.D. from the University of Pennsylvania. He completed residencies (including serving as Chief Resident) in pediatrics and neurology as well as a clinical fellowship in neonataology at Children & middots Hospital-Boston, Harvard Medical School. He became a faculty physician in the Department of Pediatrics, Children & middots Hospital-Boston and while serving as a research fellow in the Department of Genetics, Harvard Medical School. He established a lab at Children & middots Hospital-Boston in 1992. In 2003, Dr. Snyder was recruited to the Burnham Institute for Medical Research as Professor and Director of the Program in Stem Cell & Regenerative Biology. He then inaugurated the Stem Cell Research Center and initiated the Southern California Stem Cell Consortium. He serves on multiple editorial boards, published extensively in the stem cell literature, holds multiple patents in the stem cell space, and received numerous honors and lecturers widely and internationally.

Fundamental stem cell biology
Developmental neuroscience
Neural transplantation
Developmental biology
Cellular (in vitro) and animal models of disease Differentiation of pluripotent and multipotent stem cells
Neurodegenerative diseases
Neural injury and repair
Ethics and public policy
Science education

Samy L Habib is an Assistant Professor of the Department of Medicine, The University of Texas, Health Science Center, San Antonio, USA, and has strong background in molecular carcinogenesis, with specific training and expertise in several research areas. He was a co-investigator on several previous and current projects funded by ADA, NKF, AHA, VA and NIH. Attesting to his national visibility, he has been selected to serve as a regular reviewer for the Medical Research Program of the Department of Defense and Editorial Board Member of 2 Journals.

Carcinogenesis in diabetes, Mutations in DNA repair gene in diabetes and cancer,Role of Tuberin in Neuronal Degeneration,Role of Tuberin in Renal Hypertrophy and Fibrosis, Role of Tuberin in Tumorigenesis, Role of tuberin/mTOR pathway in apoptosis. (1) Understanding the role of oxidant stress in the pathogenesis of renal cell carcinoma (2) Screening cancer and diabetic patients for DNA repair gene mutation(s) (3) Explore the mechanism of renal hypertrophy and fibrosis in diabetic patients (4) Study the mechanism by which TSC2 gene regulates the DNA damage (8-oxodG) and repair (OGG1) pathways and other signal transduction including cell cycle proteins in the pathogenesis of renal carcinogenesis (5) study the role of tuberin/mTOR pathway in apoptosis in diabetes (6) Study the role of tuberin/mTOR pathway in the regulation of the neuronal damage in Alzheimers diseases (AD) and Parkinson diseases

Ivan Rich obtained his Ph.D in 1978 at the University of Ulm, in Germany and performed his postdoctoral studies at the University of Chicago. Prior to starting HemoGenix, a contract services and assay development company in 2000 where he is CEO, he was Director of Basic Research in the Division of Bone Marrow Transplantation and Professor at the University of South Carolina. He has published 50 peer-reviewed articles and edited two books. His primary field of expertise is in developmental, experimental and applied clinical hematology.

Developmental, experimental and applied clinical hematology

Samir A Farghaly is a Physician/Scientist, and faculty member of the Medical College of Cornell University and the New York Presbyterian Hospital /Cornell University Medical Center, New York, NY, USA. He received his M.D Degree from University College London University (1985), and his PhD Degree in molecular biology from London university (1993). He received several clinical and research awards. He has been an invited speaker in several national and international conferences on cancer. He is a member of several national and international societies, organization and foundation of cancer and women health . He is an editor, member of editorial boards and reviewer of several medical journals of Oncology, Gynecology and Gynecological Cancers. He has published 74 articles. He is an editor of a book on ovarian cancer.

Bio markers profile, and screening for ovarian cancer. Mutant BRCA1 and BRCA2 genes profiles in ovarian cancer. Proteomic profiling of metastatic genes of ovarian cancer. Targeted molecular therapy for advanced epithelial ovarian cancer. Minimally invasive surgery for gynecological cancer.

Marek Malecki MD PhD is President of Phoenix Biomolecular Engineering Foundation, Chief Executive Officer of the Center for Molecular Medicine, and Visiting Professor at the University of Wisconsin. He earned MD degree at the Medical Academy, Poznan followed by Residency/Fellowship in Molecular Medicine in Rigshospitalet, Copenhagen. He earned PhD at the National Academy of Sciences, Warsaw followed by the postdoctoral fellowships in molecular biology at the Austrian Academy of Sciences, Karolinska Institutet, Stockholm, Salzburg and Vienna, ETH, Zurich, Utrecht University Medical School, Utrecht, Cancer Center, Vienna, Cancer Center, Amsterdam, Biozentrum, Basel. Dr Malecki developed a novel technology to identify and isolate single living pluripotent stem cells followed by their clonal expansion and molecular profiling including sequencing their proteomes, transcriptomes, and genomes. This technology serves also for reprogramming the stem cells for their use as the vectors in gene therapy of cancer. The technology, protected by the US and WIPO, is currently streamlined to clinical trials. He is the first author on the peer-reviewed articles. He is often an invited speaker and courses faculty at the international professional conferences. Dr Malecki is Editor in Chief of the Journal of Genetic Syndromes and Gene Therapy and member of the Editorial Boards for many high-impact professional journals. He is the member of the American Medical Association, American Association of Human Genetics, American Antibody Society, Southern California Biotechnology Council, and Rho Chi Honor Society for Excellence in Teaching and as the Faculty Role Model.

Cancers of ovaries, cancers of testes, cancer stem cells (CSC), circulating tumor cells (CTCs), genetic disorders, iatrogenic genetic mutations, gene therapy, targeted gene delivery, fertility sparing therapy, biobanking, in vitro fertilization

Eldad Zacksenhaus is an Associate Professor in the Department of Medicine, Department of Laboratory Medicine & Pathobiology and the Department of Medical Biophysics, University of Toronto.

Breast cancer and the tumor suppressor pRb pathway.

Song Xin is working as a Professor in the Third Affiliated hospital, Kunming Medical College, China.

Signal transduction, Cell Cycle Biochemotherapy and Molecular Carcinogenesis. Preclinical/clinical development of molecularly targeted cancer therapeutic agents and signaling networks, including molecular mechanism studies in vitro and in vivo of therapeutic agents and molecular carcinogenesis. Current research mainly focuses on investigation of the molecular and signaling transduction pathways. Most agents are the regulators of signal transduction, cell cycle, apoptosis, angiogenesis, metastasis, differentiation, proteasome inhibition and DNA damage. Signal transduction including post translational modifications (acetylation, methylation, phosphorylation, cleavage) and molecular biologic events. The main signal transduction pathways he has studied are Ras/Raf/MEK/Erk, PKC/MAPK, PI3K/PKB/GSK3, (NFk-B, PKA, proteasome, differentiation, cell cycle, caspase, cell death receptor, cell growth receptor) etc.

Kapil Bharti obtained his Ph.D. from Johann Wolfgang Goethe University in Frankfurt, Germany, graduating summa cum laude. His Ph.D. work involved research in the areas of heat stress, chaperones, and epigenetics. He did his postdoc at the NIH, where he published numerous papers in the areas of transcription regulation, pigment cell biology, and developmental biology of the eye. He has won several awards, including, most recently, being a finalist in the prestigious trans-NIH Earl Stadtman Tenure-Track Symposium. His current work as the Head of the Unit on Ocular Stem Cells and Translational Research at NEI, NIH involves developing cell-based therapy for retinal degenerative diseases using induced pluripotent stem cell technology.

Stem Cell, Epigenetics, Cancer

Paul L. Hermonat completed his Ph.D. at the University of Florida in 1984, and postdoctoral studies at the National Institutes of Health. He is a professor of Internal Medicine and OB/GYN at the University of Arkansas for Medical Sciences and a Research Career Scientist at the Central Arkansas Veterans Healthcare System. He was the first to generate recombinant adeno-assocociated virus (AAV/NeoR) and to transfer genes into cells via this method. He has over 140 manuscripts published, mostly on the topic of AAV molecular biology and gene transfer.

AAV molecular biology and gene transfer

Eric Halioua is CEO at Promethera Biosciences, a biotechnology company that discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way. He was also a Board Member of a French biotechnology company called Vivalis, which specializes in the production of avian stem cells lines for the production of vaccines and recombinant proteins.

Corporate strategy, marketing, business development and licensing-in/out, founder of biotechnology companies

Richard G. Pestell, MB, BS, MD, PhD, MD (Hon. Causa), FACP, FRACP, MBA, Director, Kimmel Cancer Center, Vice President, Oncology Services, Associate Dean, Cancer Programs, Chairman, Department of Cancer Biology. Dr. Pestell received his MD (MBBS) from the University of Western Australia and his PhD degree from the University of Melbourne. He undertook post doctoral and clinical training in Hematology/Oncology and Endocrinology. As the single Australian recipient of the Royal Australian College of Physicians Winthrop traveling scholar and Neil Hamilton Fairley Scholar (1991-1994), he continued research at Harvard University and served as clinical fellow at Massachusetts General Hospital. Prior to his current position at the Kimmel Cancer Center, Dr. Pestell was Director of the Lombardi Cancer Center, Associate Vice President of the Medical Center at Georgetown University and Board member of the Georgetown University Hospital in Washington, DC. Dr. Pestell has authored 388 original publications and book chapters and 187 published abstracts. His work is highly cited (~27,500 citations, H-index:88). His papers have been published in prominent peer reviewed journals including Cell, Science, Nature Medicine, Molecular Cell and EMBO J. In March 2002, he was ranked first in the world for increase in total scientific impact in biology and first in the world for biochemistry (ISI). Dr. Pestell is funded as the Principal Investigator of six RO1 grants and Principal Investigator of the Kimmel Cancer Center CCSG grant. Dr. Pestell has received a number of awards for his scientific discoveries in breast and prostate cancer, including the Harrison Award (highest award of the Australian Endocrine Society), Fellow of the Royal Society of Medicine(UK), Doctor HonorisCausa, (University of Western Australia), elected membership to the American Society of Clinical Investigators, the Irma T. Hirschl Weil Caulier Career Scientist Award, Diane Belfer Faculty Scholar in Cancer Research, the Pfeiffer Award, and elected fellow to the American Association for the Advancement of Science. Dr. Pestell serves as a reviewer for 11 funding agencies and has been an active member of NIH study sections (RO1, SPORES, Cancer Centers, Program projects). Dr. Pestell has been a reviewer for 25 distinct scientific journals (currently an active editorial board member of seven journals) and has served on the externaladvisory board of six NCI-designated cancer centers.

Cancer, Molecular Biology

Jagat R Kanwar is an immunologist and molecular biochemist with an international reputation in investigating fundamental and applied molecular aspects of cancer and chronic inflammation. He did his PhD from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Before joining Deakin University in 2006, he was a Senior Scientist/Senior Research Fellow in the University of Auckland, Auckland, New Zealand. During the past decade his research both, academic and commercial has centered on understanding the pathophysiological mechanisms and/or finding treatments for a variety of chronic inflammatory diseases and different types of cancer. Dr. Kanwar has published 55 research articles, 12 invited reviews and 5 book chapters, in highly ranked, international, peer-reviewed journals. These publications have added to the body of knowledge in the fields of immunology, cancer gene therapy, nanomedicine, cell biology and biotechnology, and have extended these disciplines. He is a key inventor on 9 international patents and has provided consultancy to 5 Biotechnology based companies. He is a member of editorial board for 7 international journals and a nominated member of more than 12 national and international societies including American Society of Nanomedicine. He has extensive and close collaborations with colleagues from New Zealand, Australia, Singapore, India, China and USA.

Nanotechnology based drug delivery of proteins/peptides, siRNA and miRNA to target cancer and chronic inflammation drug discovery for novel anticancer targets for cancer cell survival, death, arrest, and repair development of immunomodulatory and anti-inflammatory bioactives, proteins and peptides for neuroprotection development of complementary alternative medicine from the milk derived proteins including metal binding protein (Lactoferrin), and herbal preparation derived active components with a special focus on the treatment of solid tumours (colon and breast cancers)

Munis Dundar was born in 1961. He graduated from Faculty of Medicine, Erciyes University (Turkey) in 1985. He obtained his Ph.D in Genetics from the Glasgow University (UK) in 1994 and M.D in Clinical Genetics in Faculty of Medicine, Osmangazi University (Turkey). He is president of the European Biotechnology Thematic Network Association (EBTNA). He is a board of the European Predictive, Preventive and Personalized Medicine Association (EPMA) and EPMA Journal. He has published more than 60 papers in reputed journals.

His Research ineterest is Clinical genetics, molecular biology, genetics.

Hilal Arnouk, MD, PhD is the Director of Research and Development at Cell Constructs, Inc. affiliated with Georgia State University. He has received his education and post-doctorate training at Roswell Park Cancer Institute, Medical College of Georgia and University of Alabama at Birmingham. His major areas of expertise include Cancer Immunotherapy, Biomarker Discovery, Stem Cells and Regenerative Medicine. He recently edited a book on Tumor Immunotherapy and Cancer Vaccines.

Cancer, Stem Cells, Regenerative Medicine, Immunotherapy